FDA BCG coverage for business development, investment, and market access teams
The FDA has approved Durvalumab and BCG for patients with high-risk non-muscle invasive bladder cancer (NMIBC). This approval marks a significant development in oncology treatment options.
We use cookies to enhance your experience, analyze traffic, and for marketing. By continuing to use our site, you consent to our use of cookies. Privacy Policy
